Cytosorbents (CTSO) Non Operating Income (2010 - 2026)

Cytosorbents' Non Operating Income history runs 17 years deep, the most recent figure standing at -$2.1 million for Q1 2026.

• Quarterly Non Operating Income fell 244.63% year-over-year to -$2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.7 million (up 274.45% YoY) and the FY2025 annual result came in at $6.1 million, up 539.6% from the prior year.
• Non Operating Income was -$2.1 million for Q1 2026 at Cytosorbents, down from $8.0 million in the prior quarter.
• Across five years, Non Operating Income topped out at $8.0 million in Q4 2025 and bottomed at -$3.2 million in Q3 2022.
• A 5-year average of $301237.4 and a median of -$588000.0 in 2024 frame the typical range for Non Operating Income.
• Annual changes were most pronounced in 2022 — Non Operating Income slumped 19394.46% — and 2025, when it jumped 714.72%.
• Cytosorbents' Non Operating Income stood at $7.0 million in 2022, then plunged by 61.61% to $2.7 million in 2023, then slumped by 148.43% to -$1.3 million in 2024, then soared by 714.72% to $8.0 million in 2025, then tumbled by 126.01% to -$2.1 million in 2026.
• Business Quant data shows CTSO's Non Operating Income at -$2.1 million in Q1 2026, $8.0 million in Q4 2025, and -$645000.0 in Q3 2025.